

ELTROMBOPAG FOR TREATMENT OF AUTOIMMUNE THROMBOCYTOPENIA ASSOCIATED WITH COVID-19 VACCINE: A CASE REPORT

B. Zurita¹, Y. Campos-Baeta¹, M. Estelrich¹, E. Sánchez², M. Martí-Navarro¹.

¹Fundació Hospital Sant Joan de Déu de Martorell, Pharmacy department. Martorell (Spain).

²Institut Català d'Oncologia, Haematology department. Martorell (Spain).

BACKGROUND AND IMPORTANCE


- Cases of thrombocytopenia, including immune thrombocytopenia (ITP), have been reported after receiving COVID-19 vaccine, typically within the first four weeks after vaccination.
- Very rarely, these events presented with very low platelet levels ($<20 \times 10^9/L$) and/or were associated with bleeding.
- Intravenous immunoglobulins and dexamethasone (high doses) are used to treat IPT secondary to COVID-19 vaccine.

AIM AND OBJECTIVES

- To describe a case of severe ITP secondary to COVID-19 vaccine successfully treated with eltrombopag.

MATERIAL AND METHODS


✓ A 60-year-old male, with clinical history of hypertension, consulted to the emergency department for **spontaneous appearance of ecchymosis and petechiae** of 10-12 days of evolution.



RESULTS

Treatment with eltrombopag 50 mg/day was started on 22 July 2021, with a platelet count of $5 \times 10^9/L$. After one week the platelet count was $4 \times 10^9/L$ so dose was raised to 75 mg/day. Five days after rising the dose, the platelet count rised to $21 \times 10^9/L$. Two days after it was $41 \times 10^9/L$ so the patient was discharged with outpatient monitoring.

On 14 October 2021 the platelet count was $101 \times 10^9/L$.



CONCLUSION AND RELEVANCE

Mild and transient thrombocytopenia is a common adverse event described for Vaxzevria®. Cases presented with very low platelet levels are very rare. Nevertheless, the benefit of vaccination continues to outweigh the risks.

We describe a severe case of ITP secondary to the COVID-19 vaccine successfully treated with eltrombopag after failure of systemic corticosteroids.

Keywords: Eltrombopag, COVID-19, Vaccine, Thrombocytopenia

Abstract number: 4CPS-249

Contact: bzurita@hmartorell.es